Park Subin, Marinov Anton, Clarke Hance, Schiavo Simone, Greer Elise, Djaiani George, Tarshis Jordan, Katznelson Rita
Temerty Faculty of Medicine, Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.
Hyperbaric Medicine Unit, Toronto General Hospital, Toronto, Ontario, Canada.
PLoS One. 2025 Jan 14;20(1):e0317586. doi: 10.1371/journal.pone.0317586. eCollection 2025.
Hyperbaric oxygen therapy (HBOT) is well established as a treatment for various medical conditions. However, it poses a risk of oxygen toxicity, which can cause seizures particularly in individuals with pre-existing seizure disorders. Consequently, seizure disorders are considered a relative contraindication to HBOT. Despite this, the relative risk of HBOT-induced seizures in this patient population remains unclear. This retrospective cohort study aims to evaluate the safety of HBOT among patients with pre-existing seizure disorders.
After obtaining approval from the Research Ethics Board, we retrospectively reviewed the patient charts of individuals with a history of seizures who were referred to the Rouge Valley Hyperbaric Medical Center and Toronto General Hyperbaric Medicine Unit for HBOT between January 2020 and December 2023. Relevant demographic information, past medical history, and HBOT session treatment protocols, such as the treatment pressure set in absolute atmospheric pressure (ATA) and number of air breaks, were recorded. The collected data was analyzed using descriptive statistics.
A total of 43 patients were referred to HBOT during the study period, and 21 patients did not proceed with the treatments. In total, 634 HBOT sessions were administered to 22 patients in monoplace chambers with five-minute air breaks, and one patient experienced a seizure event. Each patient completed an average of 29 (range 3-60) sessions lasting 90-120 minutes at 1.8 ATA (n = 3), 2.0 ATA (n = 18), or 2.4 ATA (n = 1). Fifteen patients were on oral antiseizure medications during the HBOT course. The overall incidence of seizures was one in 634 treatments.
While patients with a history of seizures may develop seizure activity during HBOT, the majority can safely undergo treatment when predetermined protocols are followed. With careful management and adherence to established protocols, HBOT can be a viable treatment option for those with seizure histories.
高压氧疗法(HBOT)作为治疗多种疾病的方法已得到广泛认可。然而,它存在氧中毒风险,尤其在已有癫痫疾病的个体中可能引发癫痫发作。因此,癫痫疾病被视为HBOT的相对禁忌证。尽管如此,该患者群体中HBOT诱发癫痫发作的相对风险仍不明确。这项回顾性队列研究旨在评估已有癫痫疾病患者接受HBOT的安全性。
在获得研究伦理委员会批准后,我们回顾性查阅了2020年1月至2023年12月期间因HBOT被转诊至鲁治谷高压医学中心和多伦多综合高压医学科的有癫痫病史患者的病历。记录了相关人口统计学信息、既往病史以及HBOT疗程治疗方案,如以绝对大气压(ATA)设定的治疗压力和空气间歇次数。使用描述性统计方法对收集的数据进行分析。
在研究期间,共有43例患者被转诊接受HBOT,其中21例患者未进行治疗。总共对22例患者在单人舱中进行了634次HBOT疗程,每次疗程有5分钟的空气间歇,有1例患者发生了癫痫发作事件。每位患者平均完成29次(范围3 - 60次)疗程,每次疗程持续90 - 120分钟,治疗压力为1.8 ATA(n = 3)、2.0 ATA(n = 18)或2.4 ATA(n = 1)。15例患者在HBOT疗程期间服用口服抗癫痫药物。癫痫发作的总体发生率为634次治疗中有1次。
虽然有癫痫病史的患者在HBOT期间可能出现癫痫活动,但大多数患者在遵循预定方案时可以安全地接受治疗。通过仔细管理和遵守既定方案,HBOT对于有癫痫病史的患者可以是一种可行的治疗选择。